A 37 weeks' gestation patient with a scheduled nonstress test (NST) has the following vital signs recorded over two days: 2/10 1535: BP 162/100, HR 78, SpO2 100%; 2/10 1600: BP 168/100, HR 76, SpO2 100%; 2/11 1200: BP 166/100, HR 84, SpO2 99%; 2/11 1818: BP 152/86, HR 78, SpO2 99%. The nurse anticipates needing to administer Magnesium Sulfate to prevent which of the following complications?

Choice A rationalePreterm labor is defined as labor that occurs between 20 and 37 weeks of gestation. The patient is already at 37 weeks' gestation, so preterm labor is not a complication to prevent.Choice B rationaleGestational diabetes is glucose intolerance that develops during pregnancy. While elevated blood pressure can sometimes be associated with gestational diabetes, magnesium sulfate is not a primary treatment or preventative measure for this condition. Management typically involves dietary changes, exercise, and sometimes insulin.Choice C rationaleMagnesium sulfate is commonly administered in the setting of preeclampsia with severe features or eclampsia to prevent seizures. The patient's consistently elevated blood pressure readings (above 160/110 mmHg on multiple occasions) indicate severe hypertension, a key diagnostic criterion for preeclampsia with severe features, placing her at high risk for seizures (eclampsia). Magnesium sulfate acts as a central nervous system depressant, reducing neuronal excitability and thus the risk of seizures.Choice D rationaleFetal growth restriction (FGR) is a condition where the fetus does not grow at the expected rate in utero. While severe preeclampsia can contribute to FGR due to placental insufficiency, magnesium sulfate is not directly used to prevent fetal growth restriction. The primary focus of magnesium sulfate in this scenario is maternal seizure prophylaxis.